School to Reopen After Asbestos Concerns

Posted on October 17, 2016 by Admin

Howzat Newcastle, which has been closed for last 5 months because of asbestos discovery, is to reopen today. The building was closed after asbestos was discovered in the indoor gym and sports center’s roof. The repairs to the Cooks Hill building will cost the Newcastle Grammar School, which owns the building, above $2 million. The gymnasium opens today itself. Indoor sports center also will open shortly after that. Ian Jack, the General Manager, said they were gradually putting the sports center back together. He said the sports competitions would begin soon after that.

Posted in Mesothelioma News | Leave a comment

Normal School to Get Rid of Asbestos

Posted on October 15, 2016 by Admin

Normal – The initial phase of removal of asbestos will begin May 1 at a junior high school building in central Illinois. The school has been closed for the remaining school year. The estimated cost of the renovation project at Chiddix School is $3.2. The school was closed in last February as the Department of Public Health in Illinois suggested sealing 10 classrooms and conducting extensive air quality tests The renovation project includes replacing existing ceilings, lighting, carpeting and furniture. The project also includes asbestos abatement. The work is expected to be completed by the time school reopens in the fall. Asbestos cleanup has to be completed by 4th June.

Posted in Mesothelioma News | Leave a comment

Lab Celebrates Blood Cancer Awareness

Posted on October 14, 2016 by Admin

ANY LAB TEST NOW® Celebrates Blood Cancer Awareness Month Lab Testing Company Encourages Bone Marrow Donation Participation Alpharetta, GA – September 10 – September is Blood Cancer Awareness Month, observed by The Leukemia & Lymphoma Society as a means to raise awareness of blood cancers and efforts implemented to provide research and treatment. ANY LAB TEST NOW®, who has partnered with Delete Blood Cancer, is celebrating at select locations by encouraging customers to become donors by hosting swab parties, collecting monetary donations to support Delete Blood Cancer’s efforts and offering lab testing promotions. “Any Lab Test Now is proud and pleased to work with Delete Blood Cancer to provide donors with a convenient way to help save the lives of others,” said Clarissa Bradstock, CEO of ANY LAB TEST NOW. Various ANY LAB TEST NOW locations serve as collection sites on behalf of Delete Blood Cancer, an organization dedicated to helping people become bo ne marrow donors. Select sites will host swab parties during the month of September as a fun way to help donors enter into the bone marrow registry. $1 donations to Delete Blood Cancer will be collected in several sites. “I Love Swabbing” wristbands and special lab testing promotions will be available to those who volunteer to become a bone marrow donor or those who choose to make a monetary donation. Customers and donors will be encouraged to download the Charity Miles app, a free mobile application that combines healthy living with charitable donations, and exercise on behalf of The Leukemia & Lymphoma Society. Join ANY LAB TEST NOW as it supports Blood Cancer Awareness Month. To learn more about ANY LAB TEST NOW, visit anylabtestnow.com or to learn more about Delete Blood Cancer, visit deletebloodcancer.org. About ANY LAB TEST NOW® Founded in 1992, ANY LAB TEST NOW is a franchise direct access lab testing company that provides thousands of standard lab t ests to consumers and businesses in a professional, convenient and cost-effective, transparent manner. With over 150 facilities around the U.S., ANY LAB TEST NOW offers a variety of affordable and confidential lab tests to consumers and businesses including general health and wellness panels, pregnancy, HIV/STD, drug, paternity and many more tests. To learn more about ANY LAB TEST NOW, visit our website or like us on Facebook. Contact Information Terri L McCulloch ANY LAB TEST NOW® www.anylabtestnow.com +1 (832) 655-3608

Posted in Mesothelioma News | Leave a comment

Malignant Mesothelioma Therapeutic Development

Posted on October 13, 2016 by Admin

Malignant Mesothelioma – Pipeline Review, H1 2015 Illinois – United States – July 15 – Malignant Mesothelioma – Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Malignant Mesothelioma’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. To view the table of contents and know more details, please visit Malignant Mesothelioma – Pipeline Review, H1 2015. Scope – The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma – The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities – The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects – The report summarizes all the dormant and discontinued pipeline projects – A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources – Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages – A detailed assessment of monotherapy and combination therapy pipeline projects – Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type – Latest news and deals relating related to pipeline products Reasons to buy – Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies – Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage – Develop strategic initiatives by understanding the focus areas of leading companies – Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma – Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline – Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics – Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope – Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned Aduro BioTech, Inc. Advantagene, Inc. Aeolus Pharmaceuticals, Inc. Amphera BV Applied Research using OMIC Sciences, S.L. arGEN-X BV ArQule, Inc. AVEO Pharmaceuticals, Inc. Bayer AG Biogen, Inc. Bionomics Limited Biotecnol, Inc. Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Calithera Biosciences, Inc. CanBas Co., Ltd. Concordia Healthcare Corp. CritiTech, Inc. Deciphera Pharmaceuticals, LLC Eagle Pharmaceuticals, Inc. Eisai Co., Ltd. Eli Lilly and Company EnGeneIC Ltd F. Hoffmann-La Roche Ltd. Five Prime Therapeutics, Inc. Formula Pharmaceuticals, Inc. Genelux Corporation GlaxoSmithKline plc Juno Therapeutics Inc. Kyowa Hakko Kirin Co., Ltd. MedImmune, LLC Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals, Inc. MolMed S.p.A. Morphotek, Inc. Novartis AG Oncos Therapeutics Ltd. Oxford BioMedica plc Pfizer Inc. Pharma Mar, S.A. Polaris Pharmaceuticals, Inc. Sellas Inc. SentoClone International AB Synta Pharmaceuticals Corp. VasGene Therapeutics, Inc. Verastem, Inc. Virttu Biologics Limited Y’s Therapeutics Co., Ltd. Contact: Debora White Manager – Marketing debora@reportstack.com Ph: +1-888-789-6604 Reportstack Market Research

Posted in Mesothelioma News | Leave a comment

Faster Mesothelioma Diagnosis and Treatment

Posted on October 10, 2016 by Admin

New Study Could Help Make Mesothelioma Diagnosis and Treatment Much Faster; Baron and Budd Applauds Advancement, Hopes Study Can Help Patients Differentiation Between Malignant Pleural Mesothelioma and Non-Cancerous Conditions Can Help Enhance Chances for Survival DALLAS – July 02 – The Journal of Molecular Diagnostics has published a study that could be a significant help in correctly diagnosing malignant pleural mesothelioma. The disease can be extremely difficult to distinguish from reactive mesothelial proliferations, a common issue that is non-cancerous. By being able to accurately differentiate between the two conditions earlier, treatment for malignant pleural mesothelioma can take place much faster. The law firm is Baron and Budd is happy to applaud this progress is mesothelioma, a cancer that generally gets little attention. (Science Codex, June 6, 2014; http://www.sciencecodex.com/biomarkers_accurately_distinguish_mesothelioma_from_noncancerous_tissue-135150) Mesothelioma, a disease that primarily results from exposure to asbestos, can be extremely difficult to diagnose accurately. The main reason is that its symptoms often mimic those of other illnesses. The goal of the study, which is headed by Eric Santoni-Rugju, MD, PhD, is to identify microRNAs – non-coding strands of RNA – that can help differentiate between malignant pleural mesothelioma from reactive mesothelial proliferations. MicroRNAs are used to diagnose and predict the behavior of other forms of cancers. The scientists involved in the study, which took place at the Copenhagen University Hospital in Copenhagen, Denmark, used four biomarkers that can help increase the accuracy of mesothelioma diagnoses. By using microRNA strands, the accuracy of classifying tissue as malignant pleural mesothelioma or reactive mesothelial proliferations has been as high as 94 percent. “This is obviously not just excellent news – it could potentially serve as a turning point in the successful treatment of this devastating disease,” said Russell Budd, managing director of mesothelioma law firm Baron & Budd. “The strides being made by this research team could eventually bring hope to countless mesothelioma patients.” The national law firm of Baron and Budd has helped mesothelioma patients and their families for more than 35 years. ABOUT BARON AND BUDD With a history of over 35 years Protecting What’s Right for individuals, communities, and governmental entities, Baron and Budd is a well-established law firm devoted to making a positive difference. With offices in Dallas, Austin, Los Angeles and Baton Rouge, Baron and Budd is able to take on complicated and expensive cases within the realms of dangerous drugs and medical devices, asbestos-related illnesses, consumer fraud, water contamination, the Gulf oil spill and fraudulent financial practices. Contact Information Amanda Billo Baron & Budd baronandbudd.com

Posted in Mesothelioma News | Leave a comment

Innovations in Asbestos Cancer Care

Posted on October 6, 2016 by Admin

The Path to a Cure: Mediaplanet Releases “The Fight Against Cancer” Campaign Cross-platform campaign celebrates the collaborative research and innovations in cancer care, and highlights the further efforts needed on the path to finding a cure New York, NY – September 05 – Mediaplanet today announces the distribution of the latest edition of “The Fight Against Cancer,” a cross-platform campaign which showcases innovations in cancer research and demands further attention around the topic. The industry has experienced a collaborative surge in research, leading to the most promising advancements in treatment and technology within the last century. Despite the vast strides being made, further research and funding is needed in order to ultimately find a cure. This campaign serves to inspire readers to take a proactive approach to their health and to funding efforts to drive research. “Today, nearly 14 million Americans are cancer survivors as new therapies ar e allowing people with cancer to live longer and with a better quality of life,” explains Peter P. Yu, M.D. FASCO, President, American Society of Clinical Oncology in the campaign’s foreword piece. He goes on to say, “New cancer cases are expected to double by 2020 as the population ages. We must achieve more, faster, through greater investment in cancer clinical trials.” The campaign features an exclusive interview with award-winning actor and advocate Patrick Dempsey, who graces the cover of the print component. In his interview, he opens up about his own family’s battle with cancer, advocates for involvement in community cancer initiatives, and encourages readers never to take time with family for granted. He stresses, “Life is short no matter how old you are. Live life to the fullest, spending time with family is very important.” The print component of “The Fight Against Cancer” is distributed within this weekend’s edition of USA Today in New York, Washingt on D.C., Baltimore, Chicago, Denver, Dallas, Philadelphia, and Seattle, with a circulation of approximately 450,000 copies and an estimated readership of 1.3 million. The digital component is distributed nationally through a vast social media strategy and across a network of top news sites and partner outlets. To explore the digital version of the campaign, click here. This campaign was made possible with the support of ASCO, American Cancer Society, Stand Up To Cancer, Patrick Dempsey, The Value of Medical Innovation, Siemens, Accuray, Bavarian Nordic, Novocure, My Life Is Worth It!, Koch Institute at MIT, Sarcoma Foundation of America, Room Key and many more. About Mediaplanet Mediaplanet is the leading independent publisher of content-marketing campaigns covering a variety of topics and industries. We turn consumer interest into action by providing readers with motivational editorial, pairing it with relevant advertisers, and distributing it within top newspap ers and online platforms around the world. Contact: Kelsey MacArthur kelsey.macarthur(at)mediaplanet(dot)com 646-922-1404

Posted in Mesothelioma News | Leave a comment

Street Reopens after Asbestos Concerns

Posted on October 5, 2016 by Admin

St. Louis – Crews have removed asbestos off a downtown block, according to city officials. The Lucas Avenue and 11th Street (North) sections, which had been closed following a steam pipe break released asbestos fibers into the air, were reopened following health director Pam Walker said the test results confirmed there were no dangerous levels of asbestos. The pipe ruptured last week sent a steam cloud above downtown streets, carrying fibers from asbestos insulation with it. The city shut the streets and started swabbing surfaces for asbestos fibers. Results of surface test indicated the presence of asbestos all through the one-block portion southwest of the pipe rupture. However, air monitors have not discovered airborne asbestos fibers, according to Walker. The north of Lucas Avenue will remain closed until the ruptured pipe is repaired. According to officials, it may take up to 10 days.

Posted in Mesothelioma News | Leave a comment

Antimetabolite Chemotherapy with Gemcitabine

Posted on October 5, 2016 by Admin

Research Finds Survival Benefit in Second Line Chemotherapy, Reports Surviving Mesothelioma There is new evidence that second-line chemotherapy with a drug called gemcitabine can significantly prolong survival in people with malignant pleural mesothelioma. Raleigh, NC – June 30 – A new study out of Turkey finds that mesothelioma patients who have second-line chemotherapy with the antimetabolite, gemcitabine (Gemzar) had a median survival rate 8 months longer than those who had only first-line chemotherapy. Surviving Mesothelioma has just posted a report on the new findings. Click here to read it now. Researchers at Acibadem Kayseri Hospital in Kayseri, Turkey examined the records of 73 mesothelioma patients from four different Turkish institutions. Those who had second-line gemcitabine-based chemotherapy were significantly more likely to still be living 36 months after treatment. “According to our results, we may consider gemcitabine-based regimens as a secon d-line chemotherapy after treatment with pemetrexed plus platinum in patients with malignant pleural mesothelioma,” writes lead researcher Dr. Hasan Mutlu, a medical oncologist with Acibadem Kayseri Hospital. The new report, published in Medical Oncology, focuses on gemcitabine because of its ability to stop DNA and RNA production in cancer cells. It is used to treat pancreatic, breast, lung, and several other cancers. “This study should offer some encouragement to patients whose mesothelioma has come back after chemotherapy that there is another, viable treatment option to try,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. To learn more about the Turkish study and survival results for mesothelioma patients on second-line gemcitabine, see Overall Survival “Significantly Higher” After Second-Line Chemotherapy, now available on the Surviving Mesothelioma website. Mutlu, H et al, “Second-line gemcitabine-based chemotherapy regimens improve overall 3 -year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study”, August 3, 201, Medical Oncology, Epub ahead of print, http://www.ncbi.nlm.nih.gov/pubmed/24958517. For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions. Contact Information Michael Ellis Cancer Monthly http://www.survivingmesothelioma.com +1 (919) 570-8595

Posted in Mesothelioma News | Leave a comment

Asbestos Lawsuit against Building Owners By City

Posted on October 3, 2016 by Admin

City Files Lawsuit against Building Owners over Asbestos Debris City authorities are trying to remove the asbestos-contaminated waste of 135 E. Main St. at the earliest after the Marshalltown grocery store burned in February. The city council had approved filing a asbestos lawsuit against F&H Properties Corp., the building owners, to force the cleanup. City lawyer Curt Ward said the city has filed a complaint claiming that the debris is a problem. The lawsuit will allow the court to seize the funds for the cleanup from F&H and hand over it to the city. F&H, which is owned by Ed Hughes and Charles Fairall, has 20 days for filing documentation. “The issue should stay in property owners’ hands. It should not be shif ted to the citizens,” Ward said.

Posted in Mesothelioma News | Leave a comment

Home Demolition Halted after Asbestos Discovery

Posted on October 2, 2016 by Admin

The demolition of a River Avenue home has been halted due to the discovery of asbestos. The MIOSHA (Michigan Occupational Safety and Health Administration) office ceased the project at because the demolition contractor hired by home owner Bank of America doesn’t have license to deal with asbestos. Mike Mason, the Asbestos Program Manager with MIOSHA, said the demolition company was advised regarding the hazards of asbestos. Mason said only accredited contractors will be allowed to remove asbestos. He said Bank of America must hire an authorized asbestos abatement contractor to evaluate the condition of asbestos and proceed further. “There is no deadline. But Bank of America will have to do it appropriately,” Mason said.

Posted in Mesothelioma News | Leave a comment